Pharmaceutical Industry 25 – 31 May: Ft HaemaLogiX, UCB and AstraZeneca
- HaemaLogiX opens enrollment for the phase 1 KOALA trial of KMCAR T-cell therapy in relapsed or refractory kappa-restricted multiple myeloma.
- UCB reports head-to-head phase 3 BE BOLD results showing bimekizumab delivered superior joint outcomes to risankizumab in active psoriatic arthritis.
- AstraZeneca secures US approval for Baxfendy, a first-in-class treatment for adults with uncontrolled hypertension.
A Week of Clinical and Regulatory Momentum for Global Pharma
The pharmaceutical industry has seen a significant wave of clinical and regulatory progress, with HaemaLogiX, UCB and AstraZeneca each announcing developments that could influence future treatment pathways in oncology, inflammatory disease and cardiovascular medicine.
While the three announcements cover very different therapeutic areas, they share a common direction of travel. Drug development is becoming more targeted, more evidence-led and more focused on patients whose conditions remain difficult to treat despite existing options.
From a first-in-human CAR-T study for multiple myeloma, to head-to-head biologic data in psoriatic arthritis, to a first-in-class hypertension approval in the United States, these updates reflect the increasingly sophisticated nature of modern pharmaceutical research.
HaemaLogiX Opens Enrolment for KOALA Trial in Multiple Myeloma
HaemaLogiX has opened patient enrolment for its phase 1 KOALA clinical trial at the Peter MacCallum Cancer Centre, marking the first human study of the company’s KMCAR T-cell therapy for relapsed or refractory kappa-restricted multiple myeloma.
The study activation follows clinical trial approval from Australia’s Therapeutic Goods Administration, as well as ethics clearance, allowing the programme to move from pre-clinical development into clinical evaluation.
The dose-escalation study will assess the safety and early efficacy of KMCAR T-cell therapy, an autologous CAR-T treatment engineered to target the tumour-specific Kappa Myeloma Antigen, known as KMA.
This antigen is found only on myeloma cells and not on healthy immune cells.
That selectivity is central to HaemaLogiX’s proposition. According to the company, the therapy may allow effective tumour killing while preserving normal immune function, potentially differentiating it from currently approved BCMA-directed CAR-T products.
A Tumour-Specific Approach to a Relapsing Cancer
Multiple myeloma remains the second most common haematological cancer worldwide, and although treatment has advanced considerably, most patients eventually relapse. For those with relapsed or refractory disease, the need for new treatment options remains urgent.
KMCAR T-cell therapy is derived from HaemaLogiX’s KappaMab antibody platform, which has already been validated across multiple phase 1, 2a and 2b studies with a favourable safety profile.
Pre-clinical work conducted with Peter Mac demonstrated specific and durable killing of KMA-positive tumour cells, supporting the decision to progress the therapy into human testing.
HaemaLogiX’s Chief Scientific Officer and Co-Founder said the milestone reflects years of scientific collaboration and a commitment to developing a targeted, tumour-specific approach for patients with relapsed or refractory multiple myeloma.
The company added that it is looking forward to the insights that the KOALA study will generate.
The company’s CEO described the commencement of patient screening and enrolment as a significant milestone at a critical time in the evolution of CAR-T therapies for multiple myeloma.
They also highlighted the therapy’s ability to target the tumour-specific KMA antigen, stating that KMCAR T-cell therapy may help broaden the therapeutic impact of CAR-T approaches in the disease.
UCB Reports Head-to-Head Psoriatic Arthritis Data
Elsewhere, UCB has announced new week 16 results from the phase 3 BE BOLD trial, showing that bimekizumab delivered superior joint outcomes to risankizumab in adults with active psoriatic arthritis.
The data were presented at the 2026 EULAR Annual Meeting in London and mark what UCB describes as the first time an approved biologic has demonstrated statistically significant superiority in joint outcomes in a head-to-head psoriatic arthritis study.
The primary endpoint was met, with 49.1% of patients receiving bimekizumab achieving ACR50 at week 16, compared with 38.4% of patients receiving risankizumab.
Early joint improvements were also seen as soon as week 4. At that point, 19.9% of patients receiving bimekizumab had achieved ACR50, compared with 7.2% of those receiving risankizumab.
Why ACR50 Matters for Patients and Clinicians
For people living with psoriatic arthritis, joint inflammation can have a major impact on mobility, pain, daily activity and quality of life. This makes higher-level clinical responses particularly important.
A Professor from the University of Glasgow stated that delivering high-level clinical responses is crucial for people with psoriatic arthritis. They explained that ACR50 responses in clinical trials indicate joint improvements that closely correlate with meaningful reductions in disease activity, better inflammation control and improvements in quality of life.
They added that the BE BOLD results, showing superiority for bimekizumab over risankizumab in ACR50 at week 16, could support clinicians in making early, informed treatment decisions for this chronic inflammatory disease.
UCB also reported numerically higher responses for bimekizumab across all secondary measures, although these did not reach statistical significance within the prespecified testing hierarchy.
Complete skin clearance, measured by PASI100 at week 16, was achieved by 53.4% of patients receiving bimekizumab and 46.6% of those receiving risankizumab.
Safety Findings Remain Consistent
No new safety signals were identified in the BE BOLD study. Candida infections were more frequent with bimekizumab, but cases were mild or moderate and none led to discontinuation.
Rates of treatment-emergent adverse events were comparable between the two treatment arms, with low and identical discontinuation rates.
UCB’s Executive Vice President said the company was proud to announce results demonstrating the superiority of bimekizumab over risankizumab in improving joint outcomes.
They added that head-to-head trials are among the most rigorous approaches to comparative clinical research and said BE BOLD reflects UCB’s commitment to generating high-quality evidence to advance care for people living with psoriatic disease.
AstraZeneca Secures US Approval for Baxfendy
AstraZeneca has also secured US approval for Baxfendy, a first-in-class aldosterone synthase inhibitor for adults whose hypertension remains uncontrolled despite treatment with other antihypertensive medicines.
The approval is based on positive phase 3 BaxHTN results, which showed statistically significant and clinically meaningful reductions in systolic blood pressure.
Hypertension affects around 1.4 billion people worldwide. AstraZeneca noted that around half of US patients continue to experience elevated blood pressure even while taking multiple therapies.
The company also highlighted hypertension as the most prevalent modifiable cardiovascular risk factor globally, contributing to deaths and disability.
Baxfendy is designed to inhibit aldosterone production. Aldosterone is a hormone that raises blood pressure and increases cardiovascular and renal risk, making it an important biological target in patients whose hypertension remains difficult to control.
A First-in-Class Option for a Persistent Global Problem
In the phase 3 BaxHTN trial, Baxfendy 2mg reduced systolic blood pressure by 15.7 mmHg from baseline, equivalent to a placebo-adjusted reduction of 9.8 mmHg.
The 1mg dose achieved a 14.5 mmHg reduction from baseline, or 8.7 mmHg placebo-adjusted. The medicine was generally well tolerated, with no unanticipated safety findings.
The primary investigator for BaxHTN said clinicians have been waiting for an innovative hypertension medication like Baxfendy for many years. They described its novel way of lowering blood pressure as having the potential to transform clinical practice by targeting a root cause of persistently uncontrolled hypertension.
They also noted that the nearly double-digit placebo-adjusted systolic blood pressure reduction achieved with Baxfendy is clinically meaningful for both clinicians and patients.
Epidemiological data indicate that a 10 mmHg decrease in systolic blood pressure is associated with a roughly 20% lower risk of serious cardiovascular events, underlining the potential significance of the trial results.
Hypertension Remains a Silent but Serious Threat
The Executive Director of the National Forum for Heart Disease & Stroke Prevention described hypertension as a staggeringly widespread silent killer and a leading risk factor for stroke, heart attack, kidney damage and dementia.
They added that tens of millions of people struggle to control their blood pressure despite lifestyle changes and existing treatments, and that innovative new treatments could help millions protect their heart, kidney and brain health.
AstraZeneca’s Executive Vice President of the BioPharmaceuticals Business Unit said the approval of Baxfendy offers a much-needed, first-in-class innovation for people living with persistently uncontrolled hypertension who have not responded to or tolerated existing medicines.
They added that in the US, around 23 million patients remain uncontrolled despite being on two or more medicines for hypertension, in a disease area that has seen relatively little therapeutic progress over the past two decades.
Impact on Pharmaceutical Manufacturing and Production
These developments also carry important implications for pharmaceutical manufacturing and production.
HaemaLogiX’s KOALA trial points to the growing importance of advanced cell therapy manufacturing, where autologous treatments require highly controlled, patient-specific production processes.
CAR-T therapies demand specialist facilities, strict chain-of-identity systems, complex logistics and close coordination between clinical sites and manufacturing partners.
UCB’s BE BOLD data reinforces the continued importance of biologics manufacturing, particularly as comparative clinical evidence increases competition between approved treatments.
As biologic therapies become more central to inflammatory disease management, manufacturers must maintain reliable production capacity, quality control and supply resilience.
AstraZeneca’s Baxfendy approval highlights a different manufacturing challenge. A first-in-class cardiovascular medicine with broad potential demand may require scalable, consistent production capable of supporting large patient populations.
Unlike highly personalised cell therapies, hypertension treatments may need significant volume readiness if adoption grows across major markets.
Together, the announcements show that pharmaceutical production is no longer moving in one direction. The industry must support both highly personalised, technically complex therapies and scalable medicines for widespread chronic disease, each with very different production demands.
Conclusion: Targeted Innovation Moves Further Into the Mainstream
The latest updates from HaemaLogiX, UCB and AstraZeneca show how modern pharmaceutical innovation is advancing across multiple fronts.
HaemaLogiX is taking a tumour-specific CAR-T therapy into human testing for a difficult-to-treat form of multiple myeloma. UCB is strengthening the evidence base for bimekizumab in psoriatic arthritis through direct head-to-head clinical data. AstraZeneca is bringing forward a first-in-class hypertension treatment for patients who remain uncontrolled despite existing medicines.
What connects these developments is not just scientific progress, but the industry’s broader shift towards treatments that are more targeted, more evidence-driven and more closely aligned with unmet patient need.
For patients, clinicians, researchers and manufacturers, these announcements represent more than isolated milestones. They point to a pharmaceutical landscape where precision, proof and production capability will increasingly define the next generation of care.
News Credits:
KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy
UCB reports positive outcomes for bimekizumab in psoriatic arthritis
AstraZeneca wins US approval for first‑in‑class Baxfendy in hypertension
Vous aimerez peut-être aussi :